Lymphoma Trial, Recruiting NCT05326919 Sponsor: Assistance Publique - Hôpitaux de Paris Condition: Lymphoma
Back to Lymphoma

Lymphoma Trial, Recruiting

NCT05326919
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been newly diagnosed with a blood or bone marrow cancer or related condition — including acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), high-risk myelodysplastic syndrome (HR-MDS), or myelofibrosis related to a blood disorder — and have not previously been treated for it
  • People who have been informed about the study and do not object to taking part
  • People who are covered by social security or any form of health insurance

Who may not be able to join:

  • People whose leukaemia or related condition has not been confirmed through laboratory examination of cells or tissue (note: people with a type of tumour called granulocytic sarcoma may still be considered — confirm with trial site)
  • People who have already received treatment for their blood condition, with some exceptions depending on their specific diagnosis — certain prior medications may be acceptable (confirm with trial site for the full list relevant to each condition)
  • People who are under legal guardianship or a court-appointed protective arrangement
  • People whose health coverage falls under a specific limited medical assistance scheme known as AME (confirm with trial site)
  • People who object to being enrolled in the eTHEMA patient registry

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 1 57 27 68 47

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
28 March 2022
Est. completion
1 March 2042

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Event Free Survival; Relapse Free Survival; Overall Survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov